Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Ruben J. Colman"'
Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine
Publikováno v:
Frontiers in Pediatrics, Vol 9 (2021)
Ulcerative colitis (UC) is a disabling disease, characterized by chronic inflammation of the colon, with a rising prevalence worldwide in the pediatric age group. Although UC presents in children with varying severity, disease extent, and comorbiditi
Externí odkaz:
https://doaj.org/article/fc08264583ce48d0b5ef54385ac9bdc6
Autor:
Ruben J. Colman, David T. Rubin
Publikováno v:
Intestinal Research, Vol 14, Iss 3, Pp 202-210 (2016)
Background/AimsUlcerative colitis (UC) patients are at greater risk for the development of colorectal neoplasia. Several individual studies have demonstrated associations between severity of histologic inflammation and colorectal neoplasia. However,
Externí odkaz:
https://doaj.org/article/99a36c72d06e4d988f6cf82efe8458e6
Publikováno v:
BMJ Open, Vol 14, Iss 3 (2024)
Introduction The only biologic therapy currently approved to treat moderate to severe Crohn’s disease in children (8 weeks and endoscopic remission (simple endoscopic severity-Crohn’s disease≤2).Ethics and dissemination ). The study protocol ha
Externí odkaz:
https://doaj.org/article/5ebc7ea38f3e4d3693b1b3581afb7b08
Autor:
Ruben J. Colman, Dana M. H. Dykes, Ana Catalina Arce-Clachar, Shehzad A. Saeed, Phillip Minar
Publikováno v:
Pediatric Inflammatory Bowel Disease ISBN: 9783031147432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81e287697b722c9812d01812eafe54bc
https://doi.org/10.1007/978-3-031-14744-9_31
https://doi.org/10.1007/978-3-031-14744-9_31
Autor:
Virginia Solitano, Antonio Facciorusso, Dermot P.B. McGovern, Tran Nguyen, Ruben J. Colman, Lily Zou, Brigid S. Boland, Silje W. Syversen, Kristin Kaasen Jørgensen, Christopher Ma, Alessandro Armuzzi, Aze Wilson, Vipul Jairath, Siddharth Singh
Publikováno v:
Clinical gastroenterology and hepatology.
Background & Aims: Identifying patients at high risk of immunogenicity is important when selecting tumor necrosis factor (TNF)-α antagonists in patients with immune-mediated inflammatory diseases (IMIDs). We evaluated the association HLA-DQA1∗05 g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a33b2e457bdd9a14566469aedde7e1d
http://www.scopus.com/inward/record.url?scp=85160062866&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85160062866&partnerID=8YFLogxK
Autor:
Ruben J. Colman, Ye Xiong, Tomoyuki Mizuno, Jeffrey S. Hyams, Joshua D. Noe, Brendan Boyle, Geert R. D’Haens, Johan van Limbergen, Kelly Chun, Jane Yang, Michael J. Rosen, Lee A. Denson, Alexander A. Vinks, Phillip Minar
Publikováno v:
Alimentary Pharmacology and Therapeutics. Wiley-Blackwell
Aliment Pharmacol Ther
Aliment Pharmacol Ther
BACKGROUND: Antibodies to infliximab (ATI) are associated with secondary loss of response and increased risk for drug reactions. Limited studies have associated ATI with increased infliximab clearance. AIMS: We assessed the impact of ATI on inflixima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77af389a6e69d73b01dac05bd7639e89
https://doi.org/10.1111/apt.16733
https://doi.org/10.1111/apt.16733
Autor:
Ruben J Colman, Abigail Samuels, Tomoyuki Mizuno, Nieko Punt, Alexander A Vinks, Phillip Minar
Publikováno v:
Inflammatory Bowel Diseases.
Lay Summary It is increasingly recognized that inconsistent biologic therapeutic response is related to pharmacokinetic variability (drug clearance) between patients. This study highlights a multidisciplinary effort to integrate a precision dosing da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e36c04751f9bf39368a32c830235efa3
https://doi.org/10.1093/ibd/izac237
https://doi.org/10.1093/ibd/izac237
Autor:
Ruben J. Colman, Phillip Minar
Publikováno v:
Alimentary pharmacology & therapeutics, 57(5), 567-568. Wiley-Blackwell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48ffc895e6db000f3f1471290fd88667
https://doi.org/10.1111/apt.17337
https://doi.org/10.1111/apt.17337
Autor:
Ruben J. Colman, Tomoyuki Mizuno, Keizo Fukushima, David B. Haslam, Jeffrey S. Hyams, Brendan Boyle, Joshua D. Noe, Geert R. D'Haens, Johan Van Limbergen, Kelly Chun, Jane Yang, Lee A. Denson, Nicholas J. Ollberding, Alexander A. Vinks, Phillip Minar
Publikováno v:
Alimentary Pharmacology and Therapeutics. Wiley-Blackwell
Background: Vedolizumab for inflammatory bowel disease (IBD) is often intensified based on distinct pharmacokinetics in children. Prior adult-specific population pharmacokinetic models have identified limited covariates of drug clearance. Aims: To es
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::944c5faa3ae09c9bb17955a036ce8e27
http://www.scopus.com/inward/record.url?scp=85141141924&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85141141924&partnerID=8YFLogxK
Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine
Publikováno v:
Frontiers in Pediatrics, Vol 9 (2021)
Frontiers in Pediatrics
Frontiers in Pediatrics
Ulcerative colitis (UC) is a disabling disease, characterized by chronic inflammation of the colon, with a rising prevalence worldwide in the pediatric age group. Although UC presents in children with varying severity, disease extent, and comorbiditi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43fabdd043f7799c03e6aa62b0c824b
https://www.frontiersin.org/articles/10.3389/fped.2021.634739/full
https://www.frontiersin.org/articles/10.3389/fped.2021.634739/full